310 related articles for article (PubMed ID: 11070993)
21. CD34+ cells from acute myeloid leukemia, myelodysplastic syndromes, and normal bone marrow display different apoptosis and drug resistance-associated phenotypes.
Suárez L; Vidriales MB; García-Laraña J; Sanz G; Moreno MJ; López A; Barrena S; Martínez R; Tormo M; Palomera L; Lavilla E; López-Berges MC; de Santiago M; de Equiza ME; Miguel JF; Orfao A
Clin Cancer Res; 2004 Nov; 10(22):7599-606. PubMed ID: 15569991
[TBL] [Abstract][Full Text] [Related]
22. Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
Yanada M; Huang X; Garcia-Manero G; O'brien S; Ravandi F; Borthakur G; Faderl S; Issa JP; Kantarjian H; Estey E
Br J Haematol; 2007 Aug; 138(4):555-7. PubMed ID: 17593249
[No Abstract] [Full Text] [Related]
23. Isochromosome 1q in a myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
Pawarode A; Finlay E; Sait SN; Barcos M; Baer MR
Cancer Genet Cytogenet; 2006 Jun; 167(2):155-60. PubMed ID: 16737916
[TBL] [Abstract][Full Text] [Related]
24. Therapy-related acute myelogenous leukemia and myelodysplastic syndrome.
Borthakur G; Estey AE
Curr Oncol Rep; 2007 Sep; 9(5):373-7. PubMed ID: 17706165
[TBL] [Abstract][Full Text] [Related]
25. Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Mattiuzzi GN; Kantarjian H; O'Brien S; Kontoyiannis DP; Giles F; Zhou X; Lim J; Bekele BN; Faderl S; Cortes J; Pierce S; Leitz GJ; Raad I; Estey E
Cancer; 2004 Feb; 100(3):568-73. PubMed ID: 14745874
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST.
Pitini V; Arrigo C; Sauta MG; Altavilla G
Leuk Res; 2009 Sep; 33(9):e143-4. PubMed ID: 19443031
[TBL] [Abstract][Full Text] [Related]
27. Myelodysplastic syndrome/acute myelogenous leukaemia related to adjuvant chemotherapy with oral pyrimidine anti-metabolites.
Abe M; Tanaka Y; Shinohara M; Kosaka M; Matsumoto T
Br J Haematol; 2000 Nov; 111(2):712-3. PubMed ID: 11122127
[No Abstract] [Full Text] [Related]
28. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy.
Balleisen S; Kuendgen A; Hildebrandt B; Haas R; Germing U
Leuk Res; 2009 Sep; 33(9):1189-93. PubMed ID: 19428106
[TBL] [Abstract][Full Text] [Related]
29. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
[TBL] [Abstract][Full Text] [Related]
30. Therapy-related acute myeloid leukaemia and myelodysplastic syndrome in Victoria, Australia 2003-2014.
Ong DM; Farrugia H; Wei A
Intern Med J; 2018 Jul; 48(7):822-829. PubMed ID: 29236346
[TBL] [Abstract][Full Text] [Related]
31. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
[TBL] [Abstract][Full Text] [Related]
32. Case report of isochromosome 17q in acute myeloid leukemia with myelodysplasia-related changes after treatment with a hypomethylating agent.
Sousa JC; Germano RT; Castro CC; Magalhaes SM; Pinheiro RF
Genet Mol Res; 2012 Aug; 11(3):2045-50. PubMed ID: 22911588
[TBL] [Abstract][Full Text] [Related]
33. Acute myeloid leukemia and myelodysplastic syndromes in older patients.
Estey E
J Clin Oncol; 2007 May; 25(14):1908-15. PubMed ID: 17488990
[TBL] [Abstract][Full Text] [Related]
34. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
35. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
[TBL] [Abstract][Full Text] [Related]
36. Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Braun T; Fenaux P
Br J Haematol; 2008 May; 141(5):576-86. PubMed ID: 18410457
[TBL] [Abstract][Full Text] [Related]
37. Granulocyte colony-stimulating factors and risk of acute myeloid leukemia and myelodysplastic syndrome.
Lyman GH; Kuderer NM
Cancer Treat Res; 2011; 157():167-78. PubMed ID: 21052956
[No Abstract] [Full Text] [Related]
38. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
39. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E
Cancer; 2003 Mar; 97(5):1234-41. PubMed ID: 12599230
[TBL] [Abstract][Full Text] [Related]
40. [Bone marrow depression following oncologic therapy].
Schwamborn J; Pfreundschuh M
Gynakologe; 1992 Apr; 25(2):71-5. PubMed ID: 1612521
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
